Elscint Holding Gamida-Cell, Teva to Develop and Commercialize StemEx

Elscint Ltd. announced that Teva Pharmaceutical Industries Ltd. has exercised its option to enter into a joint venture with Gamida-Cell Ltd., in which Elscint (through a wholly owned subsidiary) holds 29.2 percent on a fully diluted basis, in order to develop and commercialize StemEx for the treatment of Leukemia and Lymphoma.
Yahoo News